DISCLAIMER: This site is for informational purposes only. While we make every effort to keep it up to date, there is no guarantee that information is complete, accurate, comprehensive, or the same for all KP regions. The information on this site should not be interpreted or used as a substitute for professional medical care. Please consult your care provider for any personal health questions or before participating in clinical trials.

Enrollment complete

A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

NCT No.: NCT01150045

Study Type: INTERVENTIONAL

Phase: Phase III

Region: California - Northern

Acronym: 

Official Title

A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

Purpose

This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

Detailed Description

Sex

Male & Female

Age Limit

Eligibility Criteria

Inclusion Criteria

1. Requirements for tumor parameters
  1. Histologically documented adenocarcinoma of the colon. The
  gross inferior (caudad) margin of the primary tumor must lie above
  the peritoneal reflection (i.e., patients with rectal cancer are not
  eligible). Surgeon confirmation that the entire tumor was above the
  peritoneal reflection is only required in cases where it is important
  to establish if the tumor is a rectal or colon primary.
  
  2. Tumors must have been completely resected. In patients with
  tumor adherent to adjacent structures, en bloc R0 resection must
  be documented in the operative report or otherwise confirmed by
  the surgeon. Near or positive radial margin are not exclusions as
  long as en bloc resection was performed. Positive proximal margin
  or distal margin is an exclusion.

  3. Node positive disease (N1 or N2) as designated in AJCC version
  7. Either at least one pathologically confirmed positive lymph node
  or N1C (defined as tumor deposit(s) in the subserosa, mesentery,
  or nonperitonealized pericolic or perirectal tissues without regional
  lymph node metastases). Patients with resected stage IV disease
  are not eligible.
  4. No evidence of residual involved lymph node disease or
  metastatic disease at the time of registration.
  5. Patients with synchronous colon cancers are eligible and staging
  for stratification will be based on higher N stage of the more
  advanced primary tumor. However, patients with synchronous
  colon and rectal primary tumors are not eligible.

2. NSAID use
Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2 times per week (on average) or aspirin at more than 325 mg at least three times per week, on average. Low-dose aspirin not exceeding 100 mg/day is permitted. Patients who agree to stop regular NSAIDs or higher dose aspirin are eligible and no was out period is required.

3. Patient history
  1. No previous or concurrent malignancy, except treated basal cell
  or squamous cell cancer of skin, treated in situ cervical cancer,
  treated lobular or ductal carcinoma in situ in one breast, or any
  other cancer for which the patient has been disease-free for at
  least 5 years.
  2. No neurosensory or neuromotor toxicity ≥ grade 2 at the time of
  registration.
  3. No known allergy to platinum compounds.
  4. No prior allergic reaction or hypersensitivity to sulfonamides,
  celecoxib or NSAIDs.
  5. No history of upper gastrointestinal ulceration, upper
  gastrointestinal bleeding, or upper gastrointestinal perforation
  within the past 3 years. Patients with ulceration, bleeding or
  perforation in the lower bowel are not excluded.
  6. No symptomatic pulmonary fibrosis or interstitial pneumonitis ≥
  grade 2.
  7. No cardiac risk factors including:
  • Uncontrolled high blood pressure (systolic blood pressure >   
  150).
  • Unstable angina.
  • History of documented myocardial infarction or cerebrovascular
  accident.
  • New York Heart Association class III or IV heart failure.

4. Pregancy/nursing status
Non-pregnant and not nursing. Men and women of childbearing potential must agree to employ adequate contraception for the duration of chemotherapy and for as many as 8 weeks after the completion of chemotherapy due to the unknown teratogenic effects of FOLFOX on the developing fetus.

5. Age and performance status
  1. ECOG performance status 0, 1 or 2.
  2. Age at least 18 years.

6. Required initial laboratory values
  1. Granulocytes ≥ 1,500/μL
  2. Platelet count ≥ 100,000/μL
  3. Creatinine ≤ 1.5 times upper limit of normal (ULN)
  4. Total Bilirubin ≤ 1.5 times ULN in the absence of Gilbert's
  disease
  5. Direct bilirubin ≤ 1.5 x upper limit of normal for patients with
  Gilbert's syndrome

Exclusion Criteria

• pregnant and nursing

• No neurosensory or neuromotor toxicity = grade 2 at the time of registration.

• Known allergy to platinum compounds.

• Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib or NSAIDs.

• History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years. Patients with ulceration, bleeding or perforation in the lower bowel are not excluded.symptomatic pulmonary fibrosis or interstitial pneumonitis = grade 2.

• No cardiac risk factors including:;

• Uncontrolled high blood pressure (systolic blood pressure \> 150).
• Unstable angina.
• History of documented myocardial infarction or cerebrovascular   
accident.
• New York Heart Association class III or IV heart failure.   
• Pregnancy/nursing status;

• Non-pregnant and not nursing. Men and women of childbearing potential must agree to employ adequate contraception for the duration of chemotherapy and for as many as 8 weeks after the completion of chemotherapy due to the unknown teratogenic effects of FOLFOX on the developing fetus.

Keywords and/or Specific Medical Conditions

  • Gastroenterology
  • Oncology (Adult)

Sponsors

  • Alliance for Clinical Trials in Oncology

Find a study